Intravenous Fosfomycin as Adjunctive Therapy for Gram-Negative Bacteria Bloodstream Infections: A Propensity Score Adjusted Retrospective Cohort Study-Reference-Cited by-同舟云学术

Intravenous Fosfomycin as Adjunctive Therapy for Gram-Negative Bacteria Bloodstream Infections: A Propensity Score Adjusted Retrospective Cohort Study

Published:2024-08 Issue:2 Volume:64 Page:107247
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Belati Alessandra,Diella Lucia,Bavaro Davide Fiore^ORCID,De Santis Laura,Cotugno Sergio,De Gennaro Nicolò,Brindicci Gaetano,Maggiore Maria Elena,Indraccolo Francesca,Di Gennaro Francesco,Ronga Luigi,Mosca Adriana,Stufano Monica^ORCID,Dalfino Lidia^ORCID,Grasso Salvatore^ORCID,Saracino Annalisa

Publisher

Elsevier BV

Reference22 articles.

1. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli;Scudeller;Int J Antimicrob Agents,2021

2. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

3. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine);Paul;Clin Microbiol Infect,2022

4. Fosfomycin: what was old is new again;Avent;Intern Med J,2018

5. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial;Sojo-Dorado;JAMA Netw Open,2022